Pseudobulbar affect

Last updated
Pseudobulbar affect
Other namesEmotional incontinence
Specialty Psychiatry, neurology
Symptoms Episodes of uncontrollable laughing, crying, or other emotional displays that may not match the patient's mental state
DurationFew to several minutes
CausesTraumatic brain injury, ALS, MS, dementia, etc.
Risk factors Traumatic brain injury, ALS, MS, dementia, etc.
Diagnostic method During a neurological evaluation
Differential diagnosis Depression

Pseudobulbar affect (PBA), or emotional incontinence, is a type of neurological disorder characterized by uncontrollable episodes of crying or laughing. PBA occurs secondary to a neurologic disorder or brain injury. Patients may find themselves crying uncontrollably at something that is only slightly sad, being unable to stop themselves for several minutes. Episodes may also be mood-incongruent: a patient may laugh uncontrollably when angry or frustrated, for example. [1] Sometimes, the episodes may switch between emotional states, resulting in the patient crying uncontrollably before dissolving into fits of laughter.

Contents

The pseudobulbar affect, also referred to as emotional lability, should not be confused with depression that stems from emotional instability – affective dysregulation – commonly seen in mental illnesses and certain personality disorders.

Signs and symptoms

The cardinal feature of the disorder is a pathologically lowered threshold for exhibiting the behavioral response of laughter, crying, anger or all of the above. An affected individual exhibits episodes of laughter, crying, anger or a combination of these without an apparent motivating stimulus or in response to stimuli that would not have elicited such an emotional response before the onset of their underlying neurologic disorder. In some patients, the emotional response is exaggerated in intensity but is provoked by a stimulus with an emotional valence congruent with the character of the emotional display. For example, a sad stimulus provokes a pathologically exaggerated weeping response instead of a sigh, which the patient normally would have exhibited in that particular instance. [2]

However, in some other patients, the character of the emotional display can be incongruent with, and even contradictory to, the emotional valence of the provoking stimulus or may be incited by a stimulus with no clear valence. For example, a patient may laugh in response to sad news or cry in response to stimuli with no emotional undertone, or, once provoked, the episodes may switch from laughing to crying or vice versa. [3]

The symptoms of PBA can be severe, with persistent and unremitting episodes. [4] Characteristics include:

Many people with neurologic disorders exhibit uncontrollable episodes of laughing, crying, or anger that are either exaggerated or contradictory to the context in which they occur. Where patients have significant cognitive deficits (e.g., Alzheimer's) it can be unclear whether it is true PBA as opposed to a grosser form of emotional dysregulation, but patients with intact cognition often report the symptom as disturbing. Patients report that their episodes are at best only partially amenable to voluntary control, and unless they experience a severe change of mental status, as in traumatic brain injury they often have insight into their problem and judge their emotional displays as inappropriate and out of character. The clinical effect of PBA can be severe, with unremitting and persistent symptoms that can be disabling to patients, and may significantly affect quality of life for caregivers. [2]

Social impact

While not as profoundly disabling as the physical symptoms of the most common diseases that cause it (such as ALS), PBA may significantly influence individuals' social functioning and their relationships with others. Such sudden, frequent, extreme, uncontrollable emotional outbursts may lead to social withdrawal and interfere with activities of daily living, social and professional pursuits, and reduce overall healthcare. For example, patients with ALS and MS are often cognitively normal. However, the appearance of uncontrollable emotions is commonly associated with many additional neurological disorders such as attention deficit hyperactivity disorder, [5] Parkinson's disease, [6] cerebral palsy, [7] autism, [8] epilepsy, [9] and migraines. [10] This may lead to avoidance of social interactions for the patient, which in turn impairs their coping mechanisms and their careers. [4] [11] [12] [13] [14]

Several criteria exist to differentiate between PBA and depression. PBA is not depression.png
Several criteria exist to differentiate between PBA and depression.

Depression

PBA may often be misdiagnosed as clinical depression or bipolar disorder; however, many clear distinctions exist. [15]

In depressive and bipolar disorders, crying, anger or laughter are typically indicative of mood, whereas the pathological displays of crying which occur in PBA are often in contrast to the underlying mood, or greatly in excess of the mood or eliciting stimulus. In addition, a key to differentiating depression from PBA is duration: PBA episodes are sudden, occurring in an episodic manner, while crying in depression is a more sustained presentation and closely relates to the underlying mood state. The level of control that one has over the crying, anger or other emotional displays in PBA is minimal or nonexistent, whereas for those with depression, the emotional expression (typically crying) can be modulated by the situation. Similarly, the trigger for episodes of crying in patients with PBA may be nonspecific, minimal or inappropriate to the situation, but in depression the stimulus is specific to the mood-related condition. These differences are outlined in the adjacent Table.

In some cases, depressed mood and PBA may co-exist. Since depression is one of the most common emotional changes in patients with neurodegenerative disease or post-stroke sequelae, it is often comorbid with PBA. Comorbidity implies that depression is distinct from PBA and is not necessary for, nor does it exclude, a diagnosis of PBA. [16] [17]

Causes

The specific pathophysiology involved in this frequently debilitating condition is still under investigation; the primary pathogenic mechanisms of PBA remain controversial. [18] One hypothesis, established by early researchers such as Wilson and Oppenheim, placed emphasis on the role of the corticobulbar pathways in modulating emotional expression in a top-down model, and theorized that PBA occurs when bilateral lesions in the descending corticobulbar tract cause failure of voluntary control of emotion, which leads to the disinhibition, or release, of laughing/crying centers in the brainstem. [19] Other theories implicate the prefrontal cortex. [20]

Secondary condition

PBA is a condition that occurs secondary to neurological disease or brain injury, and is thought to result from disruptions of neural networks that control the generation and regulation of motor output of emotions. PBA is most commonly observed in people with neurologic injuries such as traumatic brain injury (TBI) and stroke, [19] [21] and neurologic diseases such as dementias including Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), [5] [22] multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). It has been reported as a symptom of hyperthyroidism, Graves' disease, or hypothyroidism in combination with depression. [23]

PBA has also been observed in association with a variety of other brain disorders, including brain tumors, Wilson's disease, syphilitic pseudobulbar palsy, and various encephalitides. Rarer conditions associated with PBA include gelastic epilepsy, dacrystic epilepsy, central pontine myelinolysis, olivopontinocerebellar atrophy, lipid storage diseases, chemical exposure (e.g., nitrous oxide and insecticides), fou rire prodromique , and Angelman syndrome.

It is hypothesized that these primary neurologic injuries and diseases affect chemical signaling in the brain, which in turn disrupts the neurologic pathways that control emotional expression. [24] [25] [26]

Stroke

PBA is one of the most frequently reported post-stroke behavioral disorders, with a range of reported prevalence rates from 28% to 52%. [27] [28] [29] The higher prevalence rates tend to be reported in stroke patients who are older or who have a history of prior stroke. [30] [31] The relationship between post-stroke depression and PBA is complicated, because the depressive syndrome also occurs with high frequency in stroke survivors. Post-stroke patients with PBA are more depressed than post-stroke patients without PBA, and the presence of a depressive syndrome may exacerbate the weeping side of PBA symptoms. [27] [32]

Multiple sclerosis

Recent studies suggest that approximately 10% of patients with multiple sclerosis (MS) will experience at least one episode of emotional lability. [33] [34] PBA is generally associated with later stages of the disease (chronic progressive phase). [29] PBA in MS patients is associated with more severe intellectual deterioration, physical disability, and neurological disability. [35]

Amyotrophic lateral sclerosis

A study designed specifically to survey for prevalence found that 49% of patients with amyotrophic lateral sclerosis (ALS) also had PBA. [11] PBA does not appear to be associated with duration of ALS. [36] [37] It is a symptom of ALS that many patients are unaware of and do not receive information about from their physician. [38]

Traumatic brain injury

One study of 301 consecutive cases in a clinic setting reported a 5% prevalence. PBA occurred in patients with more severe head injury, and coincided with other neurological features suggestive of pseudobulbar palsy. [39]

The Brain Injury Association of America (BIAA) indicates that approximately 80% of survey respondents experience symptoms of PBA. [40] Results from a recent investigation estimate the prevalence of PBA associated with traumatic brain injury to exceed more than 55% of survivors. [41]

Treatment

Education of patients, families, and caregivers is an important component of the appropriate treatment of PBA. Crying associated with PBA may be incorrectly interpreted as depression; laughter may be embarrassing, anger can be debilitating. It is therefore critical for families and caregivers to recognize the pathological nature of PBA and the reassurance that this is an involuntary syndrome that is manageable. Traditionally, antidepressants such as sertraline, [42] fluoxetine, [43] citalopram, [44] nortriptyline [45] and amitriptyline [46] have been prescribed with some efficacy.

Medication

Dextromethorphan hydrobromide affects the signals in the brain that trigger the cough reflex. It is used as a cough suppressant, although it can sometimes be used, medicinally, as a pain reliever, and is also used as a recreational drug. [47]

Quinidine sulfate affects the way the heart beats, and is generally used in people with certain heart rhythm disorders. It is also used to treat malaria. [48] Quinidine sulfate, as a metabolic inhibitor, "increases plasma levels of dextromethorphan by competitively inhibiting cytochrome P450 2D6, which catalyzes a major biotransformation pathway for dextromethorphan," enabling therapeutic dextromethorphan concentrations. [49]

Dextromethorphan/quinidine is a combination of these two generic drugs, and is the first FDA-approved drug for the treatment of PBA, approved on October 29, 2010. [50]

In the pivotal multicenter study that led to its approval, the "Objectives...[were] to evaluate the safety, tolerability, and efficacy of two different doses of AVP-923 [Dextromethorphan/quinidine combination]...when compared to placebo." [51] The conditions and results of that study are as follows:

At one study site, a total of 326 participants received one of three dose options. "METHODS: In a 12-week randomized, double-blind trial, ALS and MS patients with clinically significant PBA" were given a twice-daily dose of one of the following:

  • placebo (N=109)
  • dextromethorphan hydrobromide 30 mg/quinidine sulfate 10 mg (N=110)
  • Nuedexta – dextromethorphan hydrobromide 20 mg/quinidine sulfate 10 mg (N=107)

283 patients (86.8%) completed the study. The number of PBA episodes (laughing, crying or aggressive outbursts) were 47% and 49% lower (based on the trial's outcome measures), respectively, for the drug-combination options than for the placebo. The "mean CNS-LS scores" decreased by 8.2 points for both drug-combination options, vs a decrease of 5.7 points for the placebo.

Overall, the trial showed a statistically significant benefit from taking a combination of dextromethorphan and quinidine, with both dosages being safe and well tolerated. For a secondary objective measuring a participant's "perceived health status...measuring eight health concepts: vitality, physical functioning, bodily pain, general health perceptions, physical role-, emotional role-, social role functioning, and mental health," the higher dosage showed improvement, especially on measures of social functioning and mental health. [51] [52]

Epidemiology

Prevalence estimates place the number of people with PBA between 1.5 and 2 million in the United States alone, which would be less than 1% of the U.S. population even at the high end of the estimate. Some argue that the number is probably higher and that clinicians underdiagnose PBA. [53] However, the prevalence estimate of 2 million is based on an online survey. Self-selected computer-savvy patients in at-risk groups evaluated their own symptoms and submitted their self-diagnoses. No doctor or clinic confirmed the data. Motivation to participate could have been influenced by the presence of symptoms, which would have skewed the results. The actual prevalence could very well be quite a bit lower than estimated. [54]

History

The Expression of the Emotions in Man and Animals by Charles Darwin was published in 1872. [55] In Chapter VI, "Special Expressions of Man: Suffering and Weeping", Darwin discusses cultural variations in the acceptability of weeping and the wide differences in individual responses to suffering. The chapter contains the following sentence:

We must not, however, lay too much stress on the copious shedding of tears by the insane, as being due to the lack of all restraint; for certain brain-diseases, as hemiplegia, brain-wasting, and senile decay, have a special tendency to induce weeping. [55] : 156 

Terminology

Historically, there have been a variety of terms used for the disorder, including pseudobulbar affect, pathological laughter and crying, emotional lability, emotionalism, emotional dysregulation, or more recently, involuntary emotional expression disorder. [16] The term pseudobulbar ( pseudo- + bulbar ) came from the idea that the symptoms seemed similar to those caused by a bulbar lesion (that is, a lesion in the medulla oblongata).

Terms such as forced crying, involuntary crying, pathological emotionality, and emotional incontinence have also been used, although less frequently. [4]

Arthur Fleck, the central character of the 2019 film Joker , displays signs of pseudobulbar affect, [56] [57] which are said to be what Joaquin Phoenix used as inspiration for his character's signature laugh.

In the 2019 movie Parasite , the character Ki-woo sustains head trauma, and although it is not clearly mentioned that he's affected by pseudobulbar affect, he mentions not being able to stop laughing when thinking about all the events that occur in the movie.

In the 2020 movie Naan Sirithal , the character Gandhi (Hiphop Tamizha Adhi) suffers from pseudobulbar affect due to all the stress he suffers from various parts of his life gets accumulated and starts to laugh uncontrollably.

In the medical television show House , season 7, episode 8 ("Small Sacrifices"), the character Ramon Silva, played by Kuno Becker displays pseudobulbar affect, with uncontrollable incongruent laughter, while having the Marburg variety of multiple sclerosis.

In season 3, episode 9 of The Good Fight , the character Brenda DeCarlo, an external auditor, displays pseudobulbar affect, with uncontrollable incongruent laughter.

See also

Related Research Articles

<span class="mw-page-title-main">Motor neuron diseases</span> Group of neurological disorders affecting motor neurons

Motor neuron diseases or motor neurone diseases (MNDs) are a group of rare neurodegenerative disorders that selectively affect motor neurons, the cells which control voluntary muscles of the body. They include amyotrophic lateral sclerosis (ALS), progressive bulbar palsy (PBP), pseudobulbar palsy, progressive muscular atrophy (PMA), primary lateral sclerosis (PLS), spinal muscular atrophy (SMA) and monomelic amyotrophy (MMA), as well as some rarer variants resembling ALS.

<span class="mw-page-title-main">Tears</span> Clear liquid secreted from glands in eyes of mammals

Tears are a clear liquid secreted by the lacrimal glands found in the eyes of all land mammals. Tears are made up of water, electrolytes, proteins, lipids, and mucins that form layers on the surface of eyes. The different types of tears—basal, reflex, and emotional—vary significantly in composition.

<span class="mw-page-title-main">Apathy</span> State of indifference, or the suppression of emotions

Apathy, also referred to as indifference, is a lack of feeling, emotion, interest, or concern about something. It is a state of indifference, or the suppression of emotions such as concern, excitement, motivation, or passion. An apathetic individual has an absence of interest in or concern about emotional, social, spiritual, philosophical, virtual, or physical life and the world. Apathy can also be defined as a person's lack of goal orientation. Apathy falls in the less extreme spectrum of diminished motivation, with abulia in the middle and akinetic mutism being more extreme than both apathy and abulia.

<span class="mw-page-title-main">Quinidine</span> Antiarrythmic medication

Quinidine is a class IA antiarrhythmic agent used to treat heart rhythm disturbances. It is a diastereomer of antimalarial agent quinine, originally derived from the bark of the cinchona tree. The drug causes increased action potential duration, as well as a prolonged QT interval. As of 2019, its IV formulation is no longer being manufactured for use in the United States.

Conversion disorder (CD), or functional neurologic symptom disorder (FNsD), is a functional disorder that causes abnormal sensory experiences and movement problems during periods of high psychological stress. Individuals with CD present with highly distressing neurological symptoms such as numbness, blindness, paralysis, or convulsions, which are not consistent with a well-established organic cause and can be traced back to a psychological trigger.

<span class="mw-page-title-main">Alexander disease</span> Rare genetic disorder of the white matter of the brain

Alexander disease is a very rare autosomal dominant leukodystrophy, which are neurological conditions caused by anomalies in the myelin which protects nerve fibers in the brain. The most common type is the infantile form that usually begins during the first two years of life. Symptoms include mental and physical developmental delays, followed by the loss of developmental milestones, an abnormal increase in head size and seizures. The juvenile form of Alexander disease has an onset between the ages of 2 and 13 years. These children may have excessive vomiting, difficulty swallowing and speaking, poor coordination, and loss of motor control. Adult-onset forms of Alexander disease are less common. The symptoms sometimes mimic those of Parkinson's disease or multiple sclerosis, or may present primarily as a psychiatric disorder.

Witzelsucht is a set of rare neurological symptoms characterized by a tendency to make puns, or tell inappropriate jokes or pointless stories in socially inappropriate situations. It makes one unable to read sarcasm.

<span class="mw-page-title-main">Dextromethorphan</span> Cough suppressant, antidepressant, and dissociative drug

Dextromethorphan (DXM), sold under the trade name Robitussin among others, is a cough suppressant used in many cough and cold medicines. In 2022, the FDA approved the combination dextromethorphan/bupropion to serve as a rapid acting antidepressant in patients with major depressive disorder.

In medicine and psychology, emotional lability is a sign or symptom typified by exaggerated changes in mood or affect in quick succession. Sometimes the emotions expressed outwardly are very different from how the person feels on the inside. These strong emotions can be a disproportionate response to something that happened, but other times there might be no trigger at all. The person experiencing emotional lability usually feels like they do not have control over their emotions. For example, someone might cry uncontrollably in response to any strong emotion even if they do not feel sad or unhappy.

Pseudobulbar palsy is a medical condition characterized by the inability to control facial movements and caused by a variety of neurological disorders. Patients experience difficulty chewing and swallowing, have increased reflexes and spasticity in tongue and the bulbar region, and demonstrate slurred speech, sometimes also demonstrating uncontrolled emotional outbursts.

<span class="mw-page-title-main">Foix–Chavany–Marie syndrome</span> Medical condition

Foix–Chavany–Marie syndrome (FCMS), also known as bilateral opercular syndrome, is a neuropathological disorder characterized by paralysis of the facial, tongue, pharynx, and masticatory muscles of the mouth that aid in chewing. The disorder is primarily caused by thrombotic and embolic strokes, which cause a deficiency of oxygen in the brain. As a result, bilateral lesions may form in the junctions between the frontal lobe and temporal lobe, the parietal lobe and cortical lobe, or the subcortical region of the brain. FCMS may also arise from defects existing at birth that may be inherited or nonhereditary. Symptoms of FCMS can be present in a person of any age and it is diagnosed using automatic-voluntary dissociation assessment, psycholinguistic testing, neuropsychological testing, and brain scanning. Treatment for FCMS depends on the onset, as well as on the severity of symptoms, and it involves a multidisciplinary approach.

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS). Several therapies for it exist, although there is no known cure.

<span class="mw-page-title-main">Susac's syndrome</span> Medical condition

Susac's syndrome is a very rare form of microangiopathy characterized by encephalopathy, branch retinal artery occlusions and hearing loss. The cause is unknown but it is theorized that antibodies are produced against endothelial cells in tiny arteries which leads to damage and the symptoms related to the illness. Despite this being an extremely rare disease, there are four registries collecting data on the illness; two are the United States, one in Germany, and one in Portugal.

<span class="mw-page-title-main">Signs and symptoms of multiple sclerosis</span> Neurological signs and symptoms

The signs and symptoms of multiple sclerosis (MS) encompass a wide range of neurological and physical manifestations, including vision problems, muscle weakness, coordination difficulties, and cognitive impairment, varying significantly in severity and progression among individuals.

Paradoxical laughter is an exaggerated expression of humour which is unwarranted by external events. It may be uncontrollable laughter which may be recognised as inappropriate by the person involved. It is associated with mental illness, such as mania, hypomania or schizophrenia, schizotypal personality disorder and can have other causes. Paradoxical laughter is indicative of an unstable mood, often caused by the pseudobulbar affect, which can quickly change to anger and back again, on minor external cues.

<span class="mw-page-title-main">ALS</span> Rare neurodegenerative disease

Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND) or Lou Gehrig's disease in the United States, is a rare, terminal neurodegenerative disorder that results in the progressive loss of both upper and lower motor neurons that normally control voluntary muscle contraction. ALS is the most common form of the motor neuron diseases. ALS often presents in its early stages with gradual muscle stiffness, twitches, weakness, and wasting. Motor neuron loss typically continues until the abilities to eat, speak, move, and, lastly, breathe are all lost. While only 15% of people with ALS also fully develop frontotemporal dementia, an estimated 50% face at least some minor difficulties with thinking and behavior. Depending on which of the aforementioned symptoms develops first, ALS is classified as limb-onset or bulbar-onset.

<span class="mw-page-title-main">Tumefactive multiple sclerosis</span> Medical condition

Tumefactive multiple sclerosis is a condition in which the central nervous system of a person has multiple demyelinating lesions with atypical characteristics for those of standard multiple sclerosis (MS). It is called tumefactive as the lesions are "tumor-like" and they mimic tumors clinically, radiologically and sometimes pathologically.

<span class="mw-page-title-main">Differential diagnoses of depression</span> Differential diagnoses

Depression, one of the most commonly diagnosed psychiatric disorders, is being diagnosed in increasing numbers in various segments of the population worldwide. Depression in the United States alone affects 17.6 million Americans each year or 1 in 6 people. Depressed patients are at increased risk of type 2 diabetes, cardiovascular disease and suicide. Within the next twenty years depression is expected to become the second leading cause of disability worldwide and the leading cause in high-income nations, including the United States. In approximately 75% of suicides, the individuals had seen a physician within the prior year before their death, 45–66% within the prior month. About a third of those who died by suicide had contact with mental health services in the prior year, a fifth within the preceding month.

Dextromethorphan/quinidine, sold under the brand name Nuedexta, is a fixed-dose combination medication for the treatment of pseudobulbar affect (PBA). It contains dextromethorphan (DXM) and the class I antiarrhythmic agent quinidine.

<span class="mw-page-title-main">Dextromethorphan/bupropion</span> Combination medication

Dextromethorphan/bupropion (DXM/BUP), sold under the brand name Auvelity, is a combination medication for the treatment of major depressive disorder (MDD). Its active components are dextromethorphan (DXM) and bupropion. Patients who stayed on the medication had an average of 11% greater reduction in depressive symptoms than placebo in an FDA approval trial. It is taken as a tablet by mouth.

References

  1. ↑ Ramirez-Bermudez, Jesús; Perez-Esparza, Rodrigo; Flores, Jose; Leon-Ortiz, Pablo; Corona, Teresa; Restrepo-Martínez, Miguel (2022-04-01). "Involuntary Emotional Expression Disorder in a Patient With Toluene Leukoencephalopathy". Revista Colombiana de Psiquiatría. 51 (2): 163–166. doi:10.1016/j.rcp.2020.10.001. ISSN   0034-7450. PMID   33735011. S2CID   230547846.
  2. 1 2 Ahmed, Aiesha; Simmons, Zachary (2013). "Pseudobulbar affect: prevalence and management". Therapeutics and Clinical Risk Management. 9: 483–489. doi: 10.2147/TCRM.S53906 . ISSN   1176-6336. PMC   3849173 . PMID   24348042.
  3. ↑ Parvizi J, Archiniegas DB, Bernardini GL, Hoffman MW, et al. (2006). "Diagnosis and management of pathological laughter and crying". Mayo Clinic Proceedings . 81 (11): 1482–1486. doi: 10.4065/81.11.1482 . PMID   17120404.
  4. 1 2 3 Dark FL, McGrath JJ, Ron MA (1996). "Pathological laughing and crying". Australian and New Zealand Journal of Psychiatry . 30 (4): 472–479. doi:10.3109/00048679609065020. PMID   8887697. S2CID   30407097.
  5. 1 2 Skirrow, Caroline; Asherson, Philip (2013). "Emotional lability, comorbidity and impairment in adults with attention-deficit hyperactivity disorder". Journal of Affective Disorders . 147 (1–3): 80–6. doi:10.1016/j.jad.2012.10.011. PMID   23218897.
  6. ↑ Latoo, Javed; Mistry, Minal; Dunne, Francis J (2013). "Often overlooked neuropsychiatric syndromes in Parkinson's disease". British Journal of Medical Practitioners . 6 (1). Archived from the original on 4 November 2014. Retrieved 4 November 2014.
  7. ↑ Levitt S (2013). Treatment of Cerebral Palsy and Motor Delay. Wiley. ISBN   9781118699782. Archived from the original on 20 February 2017. Retrieved 4 November 2014.
  8. ↑ Atchison, B.; Dirette, D.K. (2007). Conditions in Occupational Therapy: Effect on Occupational Performance. Lippincott Williams & Wilkins. p. 40. ISBN   9780781754873. Archived from the original on 20 February 2017. Retrieved 4 November 2014.
  9. ↑ Devinsky, O; Vazquez, B (1993). "Behavioral changes associated with epilepsy". Neurologic Clinics. 11 (1): 127–49. doi: 10.1016/S0733-8619(18)30173-7 . PMID   8441366.
  10. ↑ "Medscape: Medscape Access". medscape.com. Archived from the original on 2 November 2015. Retrieved 4 November 2014.
  11. 1 2 Moore SR, Gresham LS, Bromberg MB, Kasarkis EJ, Smith RA (1997). "A self report measure of affective lability". Journal of Neurology, Neurosurgery, and Psychiatry . 63 (1): 89–93. doi:10.1136/jnnp.63.1.89. PMC   2169647 . PMID   9221973.
  12. ↑ Shaibani AT, Sabbagh MN, Doody R (1994). "Laughter and crying in neurologic disorders". Neuropsychiatry, Neuropsychology & Behavioral Neurology. 7: 243–250.
  13. ↑ Black DW (1982). "Pathological laughter. A review of the literature". Journal of Nervous and Mental Disease . 170 (2): 67–71. doi:10.1097/00005053-198202000-00001. PMID   7057172. S2CID   25616832.
  14. ↑ Green RL (1998). "Regulation of affect". Seminars in Clinical Neuropsychiatry. 3 (3): 195–200. PMID   10085207.
  15. ↑ Kekere, Victor; Qureshi, Danish; Thanju, Amod; Fouron, Patrice; Olupona, Tolulope (2022). "Pseudobulbar Affect Mimicking Depression: A Case Report". Cureus. 14 (6): e26235. doi: 10.7759/cureus.26235 . ISSN   2168-8184. PMC   9312808 . PMID   35911367.
  16. 1 2 Cummings J, Arciniegas D, Brooks B, Herndon R, Lauterbach E, Pioro E, Robinson R, Scharre D, Schiffer R, Weintraub D (2006). "Defining and diagnosing involuntary emotional expression disorder". CNS Spectrums. 11 (6): 1–7. doi:10.1017/S1092852900026614. PMID   16816786. S2CID   10565577.
  17. ↑ Espiridion, Eduardo D; Risos, Kyle N (2018). "A Major Depressive Disorder in a Patient with Pseudobulbar Affect". Cureus. 10 (12): e3746. doi: 10.7759/cureus.3746 . ISSN   2168-8184. PMC   6388818 . PMID   30820367.
  18. ↑ Archiniegas DB, Topkoff J (2000). "The neuropsychiatry of pathologic affect: an approach to evaluation and treatment". Seminars in Clinical Neuropsychiatry. 5 (4): 290–306. doi:10.1053/scnp.2000.9554. PMID   11291026.
  19. 1 2 Parvizi J, Anderson SW, Martin CO, Damasio H, Damasio AR (2001). "Pathological laughter and crying: a link to the cerebellum". Brain . 124 (Pt 9): 1708–1719. doi: 10.1093/brain/124.9.1708 . PMID   11522574.
  20. ↑ McCullagh S, Moore M, Gawel M, Feinstein A (1999). "Pathological laughing and crying in amyotrophic lateral sclerosis: an association with prefrontal cognitive dysfunction". Journal of the Neurological Sciences . 169 (1–2): 43–48. doi:10.1016/s0022-510x(99)00214-2. PMID   10540006. S2CID   34234732.
  21. ↑ Robinson RG, Parikh RM, Lipsey JR, Starkstein SE, Price TR (1993). "Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study". American Journal of Psychiatry . 150 (2): 286–293. doi:10.1176/ajp.150.2.286. PMID   8422080.
  22. ↑ Lopez, Oscar L.; Gonzalez, Maria P.; Becker, James T.; Reynolds, Charles F.; Sudilovsky, Abraham; DeKosky, Steven T. (1996). "Symptoms of depression and psychosis in Alzheimer's disease and frontotemporal dementia: exploration of underlying mechanisms". Neuropsychiatry, Neuropsychology & Behavioral Neurology. 9 (3): 154–161.
  23. ↑ Tremont Geogffery. "Neurbehavioral Functioning in Thyroid Disorders". Medicine and Health. "The Warren Alpert Medical School of Brown University" (PDF). Archived (PDF) from the original on 2015-12-23. Retrieved 2015-06-17.
  24. ↑ Greenamyre JT (1986). "The role of glutamate in neurotransmission and in neurologic disease". Archives of Neurology. 43 (10): 1058–1063. doi:10.1001/archneur.1986.00520100062016. PMID   2428340.
  25. ↑ Bittigau P, Ikonomidou C (1997). "Glutamate in neurologic diseases". Journal of Child Neurology . 12 (8): 461–485. doi:10.1177/088307389701200802. PMID   9430311. S2CID   1258390.
  26. ↑ Mattson MP (2003). "Excitotoxic and excitoprotective mechanism: abundant targets for the prevention and treatment of neurodegenerative disorders". Neuromolecular Medicine . 3 (2): 65–94. doi:10.1385/NMM:3:2:65. PMID   12728191. S2CID   13181891.
  27. 1 2 House A, Dennis M, Molyneux A, Warlow C, Hawton K (1989). "Emotionalism after stroke". BMJ . 298 (6679): 991–994. doi:10.1136/bmj.298.6679.991. PMC   1836312 . PMID   2499390.
  28. ↑ Seliger GM, Hornstein A, Flax J, Herbert J, Schroeder K (1992). "Fluoxetine improves emotional incontinence". Brain Injury . 6 (3): 267–270. doi:10.3109/02699059209029668. PMID   1581749.
  29. 1 2 Feinstein A, Feinstein K, Gray T, O'Connor P (1997). "Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis". Archives of Neurology. 54 (9): 1116–1121. doi:10.1001/archneur.1997.00550210050012. PMID   9311355.
  30. ↑ Kim JS (2002). "Post-stroke emotional incontinence after small lenticulocapsular stroke: correlation with lesion location". Journal of Neurology . 249 (7): 805–810. doi:10.1007/s00415-002-0714-4. PMID   12140660. S2CID   22019561.
  31. ↑ Harris Y, Gorelick PB, Cohen D, Dollear W, et al. (1994). "Psychiatric symptoms in dementia associated with stroke: a case-control analysis among predominantly African-American patients". Journal of the National Medical Association. 86 (9): 697–702. PMC   2607578 . PMID   7966434.
  32. ↑ Ross ED, Stewart RS (1987). "Pathological display of affect in patients with depression and right frontal brain damage. An alternative mechanism". Journal of Nervous and Mental Disease. 175 (3): 165–172. doi:10.1097/00005053-198703000-00007. PMID   3819712. S2CID   22177650.
  33. ↑ Haupt (1996). "Emotional lability, intrusiveness, and catastrophic reactions". International Psychogeriatrics. 8 (Suppl 3): 409–414. doi:10.1017/S1041610297003736. PMID   9154598. S2CID   23055485.
  34. ↑ Sloan RL, Brown KW, Pentland B (1992). "Fluoxetine as a treatment for emotional lability after brain injury". Brain Injury. 6 (4): 315–319. doi:10.3109/02699059209034945. PMID   1638265.
  35. ↑ Surridge D (1969). "An investigation into some psychiatric aspects of multiple sclerosis". British Journal of Psychiatry . 115 (524): 749–764. doi:10.1192/bjp.115.524.749. PMID   5806869. S2CID   10900202.
  36. ↑ Caroscio JT, Mulvihill MN, Sterling R, Abrams B (1987). "Amyotrophic lateral sclerosis". Neurologic Clinics. 5 (1): 1–8. doi:10.1016/S0733-8619(18)30931-9. PMID   3561382.
  37. ↑ Gallagher JP (1989). "Pathologic laughter and crying in ALS: a search for their origin". Acta Neurologica Scandinavica . 80 (2): 114–117. doi:10.1111/j.1600-0404.1989.tb03851.x. PMID   2816272. S2CID   32590792.
  38. ↑ Wicks P, Frost J (2008). "ALS patients request more information about cognitive symptoms". European Journal of Neurology . 15 (5): 497–500. doi: 10.1111/j.1468-1331.2008.02107.x . PMID   18325023. S2CID   205580014.
  39. ↑ Zeilig G, Drubach DA, Katz-Zeilig M, Karatinos J (1996). "Pathological laughter and crying in patients with closed traumatic brain injury". Brain Injury. 10 (8): 591–597. doi:10.1080/026990596124160. PMID   8836516.
  40. ↑ "BIAA Survey: Pseudobulbar Affect in Brain Injury. Summary report". December 2010. Archived from the original on 2011-09-27. Retrieved 2011-08-16.
  41. ↑ Fellus JL, Kantor D, Kaye RE (2012). "PRISM registry: A novel research tool to determine the prevalence of pseudobulbar affect". European Journal of Neurology. 19 (S1): 85–90. doi: 10.1111/j.1468-1331.2012.03887.x .
  42. ↑ Burns, Alistair; Russell, Eve; Stratton-Powell, Hilary; Tyrell, Pippa; O'Neill, Paul; Baldwin, Robert (1999). "Sertraline in stroke-associated lability of mood". International Journal of Geriatric Psychiatry. 14 (8): 681–5. doi:10.1002/(SICI)1099-1166(199908)14:8<681::AID-GPS49>3.0.CO;2-Z. PMID   10489659. S2CID   40410983.
  43. ↑ Brown, K. W.; Sloan, R. L.; Pentland, B. (1998). "Fluoxetine as a treatment for post-stroke emotionalism". Acta Psychiatrica Scandinavica . 98 (6): 455–8. doi:10.1111/j.1600-0447.1998.tb10119.x. PMID   9879787. S2CID   24075238.
  44. ↑ Andersen, G; Vestergaard, K; Riis, J. O. (1993). "Citalopram for post-stroke pathological crying". The Lancet . 342 (8875): 837–9. doi:10.1016/0140-6736(93)92696-Q. PMID   8104273. S2CID   24445214.
  45. ↑ Robinson, RG; Parikh, RM; Lipsey, JR; Starkstein, SE; Price, TR (1993). "Pathological laughing and crying following stroke: Validation of a measurement scale and a double-blind treatment study". American Journal of Psychiatry. 150 (2): 286–93. doi:10.1176/ajp.150.2.286. PMID   8422080.
  46. ↑ Schiffer, Randolph B.; Herndon, Robert M.; Rudick, Richard A. (1985). "Treatment of Pathologic Laughing and Weeping with Amitriptyline". The New England Journal of Medicine . 312 (23): 1480–2. doi:10.1056/NEJM198506063122303. PMID   3887172.
  47. ↑ "Dextromethorphan (DXM)". Cesar.umd.edu. Archived from the original on 2013-07-26. Retrieved 2016-02-18.
  48. ↑ "Quinidine sulfate". PDRhealth™. 2016. Archived from the original on 2015-09-05. Retrieved 2016-02-18.
  49. ↑ "Label: NUEDEXTA- dextromethorphan hydrobromide and quinidine sulfate capsule, gelatin coated". U.S. National Library of Medicine, DailyMed. 2015-01-30. Archived from the original on 2016-03-03. Retrieved 2016-02-18.
  50. ↑ "Nuedexta, FDA Approval History". Drugs.com. January 2015. Archived from the original on 2016-03-03. Retrieved 2016-02-18.
  51. 1 2 "Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS (STAR)". ClinicalTrials.gov. June 2013. Archived from the original on 2016-03-02. Retrieved 2016-02-19.
  52. ↑ Pioro, Erik P.; Brooks, Benjamin Rix; Cummings, Jeffrey; Schiffer, Randolph; Thisted, Ronald A.; Wynn, Daniel; Hepner, Adrian; Kaye, Randall (2010). "Dextromethorphan Plus Ultra Low-Dose Quinidine Reduces Pseudobulbar Affect". Annals of Neurology . 68 (5): 693–702. doi:10.1002/ana.22093. PMID   20839238. S2CID   2824842.
  53. ↑ Archiniegas DB, Lauterbach EC, Anderson KE, Chow TW, et al. (2005). "The differential diagnosis of pseudobulbar affect (PBA). Distinguishing PBA among disorders of mood and affect. Proceedings of a roundtable meeting". CNS Spectrums. 10 (5): 1–16. doi:10.1017/S1092852900026602. PMID   15962457. S2CID   45811704.
  54. ↑ Brooks, Benjamin Rix; Crumpacker, David; Fellus, Jonathan; Kantor, Daniel; Kaye, Randall E (Aug 21, 2013). "PRISM: A Novel Research Tool to Assess the Prevalence of Pseudobulbar Affect Symptoms across Neurological Conditions". PLOS ONE . 8 (8). Public Library of Science: e72232. Bibcode:2013PLoSO...872232B. doi: 10.1371/journal.pone.0072232 . PMC   3749118 . PMID   23991068.
  55. 1 2 Darwin, Charles (2008) [1872]. "Expression of the Emotions". Archived from the original on 2013-11-18. Retrieved 2013-10-26.
  56. ↑ "Joaquin Phoenix Reveals the Dark, Real World Origin of His Joker's Laugh". CBR. 14 August 2019. Retrieved 12 October 2019.
  57. ↑ Skryabin, Valentin Yurievich (2021). "Analysing Joker: an attempt to establish diagnosis for a film icon". BJPsych Bulletin. 45 (6): 329–332. doi:10.1192/bjb.2020.146. ISSN   2056-4694. PMC   8727382 . PMID   33407973.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.